- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07940712
Cognitive Augmentation, Remediation, and TDCS for Schizophrenia (CARTS)
Cognitive Augmentation, Remediation, and TDCS for Schizophrenia (CARTS)
Schizophrenia-spectrum disorders (SSDs; schizophrenia, schizoaffective disorder, etc.) are among the most disabling and costly conditions globally. Most SSD medications treat symptoms like hallucinations and delusions, but cognitive symptoms, or problems with thinking, memory, and problem solving, remain untreated by medication. Other developing treatments for these symptoms include noninvasive stimulation of cognitive brain regions and behavioral therapies involving mental skill-building activities. While both of these treatments appear to improve cognitive symptoms, effects are inconsistent depending on specific details of the trial. Growing evidence suggests that using these therapies together could lead to larger, clinically meaningful effects. Still, prior combined therapy trials use simplified versions of the behavioral therapy, omitting the guidance of a therapist to engage and challenge the participant. These previous trials show some evidence for beneficial effects, particularly in working memory, but the omission of a therapist could limit effects. This study will be the first to test if using a comprehensive, therapist-guided behavioral therapy can amplify the effects of noninvasive brain stimulation (NIBS) to reduce cognitive symptoms and change brain activity in SSDs. We will conduct a small pilot study to gather preliminary evidence for this combined therapy using 10 participants split into 2 groups. One group will receive NIBS and comprehensive cognitive therapy (NIBS+) while the other receives NIBS and performs quizzes without the guidance of a therapist (NIBS-). Participants will receive therapies for 10 days over 2 weeks with 2 hours of therapy per day. We will compare interventions through the following aims. Aim 1 will examine changes in brain connections after NIBS+ and NIBS-. We will collect data from electrical brain recordings (electroencephalography/EEG) before and after interventions. We expect that connections between cognitive brain regions will be most strengthened by NIBS+ compared to NIBS-. Aim 2 will investigate what kind of cognitive symptoms are affected by NIBS+ and NIBS-. We will perform cognitive tests before and after the interventions. We expect that all cognitive symptoms (memory, motor speed, language skills, attention, processing speed, and planning abilities) will be most improved by NIBS+ compared to NIBS-, but that the largest improvements will be in short-term, active memory skills ("working memory"). We will also investigate if there is a relationship between the changes in brain connections and cognitive improvements.
This preliminary study will provide early evidence that the effects of noninvasive brain stimulation can be strengthened by a structured, therapist-guided behavioral therapy for cognitive symptoms. This will support the development of a new, combined therapy for untreated cognitive symptoms in schizophrenia-spectrum disorders. We will use findings of this study to support a trial proposal to the National Institute of Mental Health to test this therapy in a larger group of individuals.
Studieoversikt
Status
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Rebekah L Trotti, PhD
- Telefonnummer: 617-754-1262
- E-post: rtrotti@bidmc.harvard.edu
Studer Kontakt Backup
- Navn: Brendan Stiltner, BS
- E-post: bstiltne@bidmc.harvard.edu
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02115
- Beth Israel Deaconess Medical Center
-
Ta kontakt med:
- Rebekah L Trotti, PhD
- Telefonnummer: 617-754-1262
- E-post: rtrotti@bidmc.harvard.edu
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder
- Proficient in English
- IQ >= 80
Exclusion Criteria:
- Major neurological conditions
- Implanted devices in the body or metal in the head
- Changes to relevant medications within 1 month of enrollment
- Pregnancy or breastfeeding
- Moderate to severe DSM V substance use disorder
- Clinical instability including recent or severe suicidal ideation or actions
- Positive urine drug screen for illicit substances
- Skin allergy to lidocaine or electrolyte gel
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: NIBS+
Combined transcranial direct current stimulation and cognitive remediation therapy (both active) |
Active HD-tDCS delivered to the left dorsolateral prefrontal cortex
Andre navn:
Active cognitive remediation therapy. Cognitive exercises are delivered with NeuropsychOnline and administered by a trained coach.
Andre navn:
|
|
Aktiv komparator: NIBS-
Transcranial direct current stimulation and sham cognitive remediation therapy (active tDCS and sham CRT) |
Active HD-tDCS delivered to the left dorsolateral prefrontal cortex
Andre navn:
An active comparator for cognitive remediation therapy, delivered with quizzes collected from Sporcle.com.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Functional connectivity with the prefrontal cortex
Tidsramme: Pre-intervention to post-intervention at 2-weeks
|
Participants will be directed to keep their eyes open and loosely fixed on a plus sign on the screen in front of them for 5 minutes while EEG is recorded. Resting data will be cleaned, processed, and transformed to 4 frequency band values: delta/theta, alpha, beta, and gamma. Frequency data will be converted to connectivity values using weighted phase lag index (wPLI). Average connectivity of all sensors with the prefrontal sensor F3 will be calculated and compared between timepoints. |
Pre-intervention to post-intervention at 2-weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Brief Assessment of Cognition Digit Sequencing (Working Memory)
Tidsramme: Pre-intervention to post-intervention at 2-weeks
|
Participants will arrange random number strings in ascending order during the Brief Assessment of Cognition. This score, which indexes working memory is called Digit Sequencing and will be z-scored according to published norms and compared between timepoints. |
Pre-intervention to post-intervention at 2-weeks
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Brief Assessment of Cognition subdomains
Tidsramme: Pre-intervention to post-intervention at 2-weeks
|
Participants will complete the Brief Assessment of Cognition, which includes tasks indexing psychomotor and visual processing speed, lexical access, attention and processing speed, and executive functioning, called Token Motor, Verbal Fluency, Symbol Coding, and Tower of London, respectively. These subdomain scores will be normed and compared between timepoints. |
Pre-intervention to post-intervention at 2-weeks
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2026P000528
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Only IPD used in the results publication will be shared.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .